{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:43:50Z","timestamp":1788983030323,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bioorg.2020.103970","type":"journal-article","created":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T10:17:31Z","timestamp":1590315451000},"page":"103970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Discovery of novel dual c-Met\/HDAC inhibitors as a promising strategy for cancer therapy"],"prefix":"10.1016","volume":"101","author":[{"given":"Hao","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2020.103970_b0005","series-title":"Kinase Inhibitor Drugs","author":"Claiborne","year":"2009"},{"key":"10.1016\/j.bioorg.2020.103970_b0010","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0021-9258(18)71184-8","article-title":"The enzymatic phosphorylation of proteins","volume":"211","author":"Burnett","year":"1954","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2020.103970_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to Gefitinib or Erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.bioorg.2020.103970_b0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1042\/BJ20080728","article-title":"Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations","volume":"415","author":"Avizienyte","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2020.103970_b0025","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.2174\/0929867325666171129215610","article-title":"Overview on anticancer drug design and development","volume":"25","author":"Olgen","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103970_b0030","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination Therapy in Combating Cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2020.103970_b0035","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: Challenges and Opportunities in Drug Discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103970_b0040","doi-asserted-by":"crossref","unstructured":"Peters; Jens-Uwe. Polypharmacology \u2013 Foe or Friend? J. Med. Chem. 2013, 56, 8955\u20138971.","DOI":"10.1021\/jm400856t"},{"key":"10.1016\/j.bioorg.2020.103970_b0045","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc1912","article-title":"Invasive growth: a MET -driven genetic programme for cancer and stem cells","volume":"6","author":"Boccaccio","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2020.103970_b0050","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1126\/science.1846706","article-title":"Identification of the hepatocyte growth factor receptor as the C-met proto-oncogene product","volume":"251","author":"Bottaro","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2020.103970_b0055","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/ijc.11471","article-title":"Increase of AKT\/PKB expression correlates with Gleason pattern in human prostate cancer","volume":"107","author":"Liao","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bioorg.2020.103970_b0060","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1158\/0008-5472.CAN-04-0272","article-title":"Phosphorylation of Akt (Ser(473)) is an excellent predictor of poor clinical outcome in prostate cancer","volume":"64","author":"Kreisberg","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2020.103970_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.09.044","article-title":"C-met as a target for human cancer and characterization of inhibitors for therapeutic intervention","volume":"225","author":"Christensen","year":"2005","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2020.103970_b0070","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET gene copy number negatively affects survival of surgically resected non\u2013small-cell lung cancer patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2020.103970_b0075","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejmech.2013.04.001","article-title":"Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-Oxy-3-fluoroaniline moiety","volume":"64","author":"Li","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103970_b0080","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.bmc.2013.04.013","article-title":"Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors","volume":"21","author":"Li","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103970_b0085","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the C-MET signaling pathway","volume":"3","author":"Organ","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.bioorg.2020.103970_b0090","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2020.103970_b0095","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone Deacetylase Inhibitor (HDACI) Mechanisms of Action: Emerging Insights","volume":"143","author":"Bose","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2020.103970_b0100","doi-asserted-by":"crossref","first-page":"722","DOI":"10.5604\/17322693.1061381","article-title":"Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications","volume":"67","author":"Grabarska","year":"2013","journal-title":"Postepy Hig Med. Dosw."},{"key":"10.1016\/j.bioorg.2020.103970_b0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bbrc.2007.11.089","article-title":"Inhibition of tumor-stromal interaction through HGF\/met signaling by valproic acid","volume":"366","author":"Matsumoto","year":"2008","journal-title":"Biochem. Biophys. Res. Co."},{"key":"10.1016\/j.bioorg.2020.103970_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543776.2013.736493","article-title":"Histone deacetylase inhibitors: a patent review (2009\u20132011)","volume":"23","author":"Carafa","year":"2013","journal-title":"Expert Opin Ther. Pat."},{"key":"10.1016\/j.bioorg.2020.103970_b0115","doi-asserted-by":"crossref","unstructured":"J.P. Laubach, J.F. San-Miguel, V. Hungria, J. Hou, N.P. Moreau, S. Lonial, J.H. Lee, H. Einsele, M. Alsina, P.G. Richardson, Expert Rev. Hematol. 10 (2017) 229\u2013237.","DOI":"10.1080\/17474086.2017.1280388"},{"key":"10.1016\/j.bioorg.2020.103970_b0120","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/med.21505","article-title":"Chimeric HDAC Inhibitors: Comprehensive Review on the HDAC-Based Strategies Developed to Combat Cancer","volume":"38","author":"Hesham","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2020.103970_b0125","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1021\/jm901453q","article-title":"Discovery of 7-(4-(3-Ethynylphenylamino)-7-Methoxyquinazolin-6-Yloxy)-N-Hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer","volume":"53","author":"Cai","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103970_b0130","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1535-7163.MCT-16-0390","article-title":"Dual HDAC and PI3K Inhibitor CUDC-907 down Regulates MYC and Suppresses Growth of MYC-Dependent Cancers","volume":"16","author":"Sun","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2020.103970_b0135","doi-asserted-by":"crossref","first-page":"14017","DOI":"10.18632\/oncotarget.14876","article-title":"Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity against B Cell Lymphoma","volume":"8","author":"Mondello","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.bioorg.2020.103970_b0140","unstructured":"Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Subjects With RR MYC-Altered DLBCL (NCT02674750). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02674750; 2016."},{"key":"10.1016\/j.bioorg.2020.103970_b0145","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1021\/acsmedchemlett.7b00172","article-title":"Design, synthesis, and biological evaluation of the first c-met\/HDAC inhibitors based on pyridazinone derivatives","volume":"8","author":"Lu","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2020.103970_b0150","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1021\/jm201330u","article-title":"Structure-based design of novel class II c-met inhibitors: 1. Identification of pyrazolone-based derivatives","volume":"55","author":"Norman","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103970_b0155","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1021\/acs.jmedchem.9b00041","article-title":"Discovery and structure-based optimization of next generation reversible methionine aminopeptidase-2 (MetAP-2) Inhibitors","volume":"62","author":"Heinrich","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103970_b0160","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","article-title":"Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2020.103970_b0165","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1021\/acs.jmedchem.8b00393","article-title":"Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for Combinational Treatment of Leukemia and Invasive Fungal Infections","volume":"61","author":"Huang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103970_b0170","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1080\/00397919808004415","article-title":"A novel synthesis of 1-aminocyclopropane-1-carboxylic acid (ACC)","volume":"28","author":"Zhu","year":"1998","journal-title":"Synth. Commun."},{"key":"10.1016\/j.bioorg.2020.103970_b0175","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1021\/cr200060g","article-title":"The methylation effect in medicinal chemistry","volume":"111","author":"Barreiro","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2020.103970_b0180","doi-asserted-by":"crossref","first-page":"12256","DOI":"10.1002\/anie.201303207","article-title":"Profound methyl effects in drug discovery and a call for new CH methylation reactions","volume":"52","author":"Schonherr","year":"2013","journal-title":"Angew. Chem."},{"key":"10.1016\/j.bioorg.2020.103970_b0185","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors","volume":"401","author":"Finnin","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2020.103970_b0190","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1021\/jm800043g","article-title":"Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase","volume":"51","author":"Albrecht","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103970_b0195","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3390\/molecules23071543","article-title":"Design, Synthesis and Biological Evaluation of 6,7-Disubstituted-4-phenoxyquinoline Derivatives Bearing Pyridazinone Moiety as c-Met Inhibitors","volume":"23","author":"Liu","year":"2018","journal-title":"Molecules"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820301206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820301206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:01:19Z","timestamp":1758614479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206820301206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":39,"alternative-id":["S0045206820301206"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.103970","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel dual c-Met\/HDAC inhibitors as a promising strategy for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.103970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103970"}}